key: cord-0923528-eaold50d authors: Denorme, Frederik; Ajanel, Abigail; Campbell, Robert A. title: Shining a light on platelet activation in COVID‐19 date: 2022-03-02 journal: J Thromb Haemost DOI: 10.1111/jth.15678 sha: 3ce95138c338dfbeef07d7dada8c77307e46e402 doc_id: 923528 cord_uid: eaold50d nan Thromboembolic complications are more commonly observed in COVID-19 patients compared to other acute medical illnesses and respiratory infections. 3, 4 Importantly, widespread pulmonary thrombosis, as found in COVID-19 autopsies, imply this coagulopathy also contributes to respiratory failure. [5] [6] [7] In addition, COVID-19 coagulopathy is independently associated with critical illness and all-cause mortality. 8, 9 With these observations in mind, several trials combined forces to evaluate therapeutic-dose versus prophylactic-dose heparin, in hospitalized COVID-19 patients (ACTIV-4a, ATTACC, and REMAP-CAP). 10, 11 These trails were halted in December 2020 for two distinct and intriguing reasons. In critical care patients, the trials were stopped due to futility, attributed to a high risk for bleeding complications. 11 Conversely, in moderately ill COVID-19 patients, the trials were halted due to superiority, demonstrating robust benefits of therapeutic-dose heparin. 10 These results highlight the complexity of COVID-19-associated coagulopathy and the importance of starting therapeutic heparin early in the disease process, before patients become critically ill. Remarkably, many of the COVID-19 autopsy studies that found evidence for micro-and macro-thrombotic events were performed on patients that were on prophylactic or therapeutic anticoagulant treatment. [4] [5] [6] [7] Likewise, the clinical trials that demonstrated superiority for anticoagulant treatment, still observed significant thrombotic events. 10, 11 This implies there is potential for additional adjunctive antithrombotic treatments, with antiplatelet drugs as the prime candidates. While classically known for their hemostatic function, platelets are also gaining recognition as an integral part of the immune system, teaming up with innate immune cells such as neutrophils and macrophages to actively trap and kill pathogens. 12 Platelets bridge the immune system and thrombosis via activation and release of hemostatic and inflammatory mediators. The dark side of this immune phenotype of platelets, however, is the collateral damage associated with systemic platelet activation. Indeed, the interplay among platelets, coagulation, and the endothelium can result in thrombotic complications, as often observed in viral and bacterial infections. 13 Likewise, it has been hypothesized that platelets contribute to thrombosis in COVID-19 patients. Platelet-rich thrombi were readily observed in COVID-19 patients, 5,14 indicating they actively participate in COVID-19-associated thrombosis. Furthermore, we and others have found that COVID-19 is associated with a hyperactive platelet phenotype, characterized by increased platelet activation, platelet extracellular vesicle release, and platelet-leukocyte and plateletendothelial cell interactions. [15] [16] [17] [18] [19] [20] Interestingly, several studies have reported a link between platelet activation markers and outcomes in COVID-19 patients highlighting potential for antiplatelet drugs in COVID-19. 15, 18, 21, 22 Antiplatelet therapy might have beneficial effects in severe COVID-19 through several mechanisms, including inhibition of platelet aggregation as well as reduction of plateletderived inflammation. 23, 24 In vitro, we and others have shown that aspirin reduces the hyperactive platelet phenotype in platelets isolated from COVID-19 patients. 20, 25 Similarly, Barrett et al. found that P2Y 12 inhibition was able to reduce platelet-mediated endothelial cell activation in COVID-19 patients. 18 However, the real-world translation of these promising findings has turned out to be not as straightforward as initially hoped. The RECOVERY trial evaluated the addition of aspirin to standard care (i.e., therapeutic heparin) and found no improvement with regard to reductions in the risk of progressing to invasive mechanical ventilation or death. 26 Nevertheless, aspirin use was associated with a slight yet significant reduction in thrombotic events, again corroborating the role of platelets in COVID-19-associated thrombosis. Unfortunately, a similar increase in bleeding events was found, potentially contributing to the net zero effect of aspirin on outcomes. 26 Despite these discouraging first results, there was the potential for other antiplatelet drugs such as P2Y 12 inhibitors to be more effective due to their potent platelet-inhibiting properties and distinct anti-inflammatory effects. 27 Nonetheless, the ACTIV-4a clinical trial again showed no effect for the combination of therapeutic dose heparin plus a P2Y 12 inhibitor in non-critically ill COVID-19 patients. 28 Intriguingly, heparin plus a P2Y 12 inhibitor did not reduce major thrombotic events compared to heparin alone. While discouraging, it is important to note that these trials assessed the effect of antiplatelet drugs on top of therapeutically dosed heparin, thereby making it difficult to detect (additional) benefit. 29 It was postulated that other drugs, more specifically targeting the thromboinflammatory effects of platelets, have a better chance at improving outcomes. However, both aspirin and P2Y 12 inhibitors have well-characterized anti-inflammatory effects indicating altering the timing of antiplatelet treatment, rather than type, could be clinically beneficial. Several observational retrospective studies have indeed found an association with pre-hospital antiplatelet drugs and improved outcomes in hospitalized COVID-19 patients. [30] [31] [32] Given the robust transcriptional differences in COVID-19 patient platelets, 20,22 observed irrespective of disease severity and time of hospital admission, it is reasonable to assume irreversible platelet changes have already taken effect before antiplatelet treatment was started in these trials. In addition to knowing when to treat patients with platelet inhibitors, it is conceivable not every COVID-19 patient would benefit the same from antiplatelet drugs. In light of this, the novel method presented by Nishikawa et al., 2 which uses fluorescent single-cell profiling of circulating platelet aggregates, has the potential to become a valuable tool to stratify COVID-19 patients in terms of platelet activation status. The ability to visualize platelet-platelet interactions and plateletleukocyte aggregates in a meaningful approach with highthroughput processing is a significant limitation with current While this novel technique will need fine-tuning and validation by other research groups, it has the potential to become a valuable additional tool to study platelet hyperactivation in patients. As platelets are key drivers of many thrombotic and inflammatory disorders, this technique could have applications that go beyond COVID-19 such as sepsis, thrombotic thrombocytopenic purpura, and ischemic stroke. While the emphasis of the current study was on COVID-19 patients, it will be important to consider this technique in other diseases in which antiplatelet drugs might not benefit all patients equally. In particular, this technique could help stratify patients who are most likely to benefit from antiplatelet therapies in diseases in which a risk for bleeding limits the efficacy of antiplatelets drugs-in the setting of stroke, for example, in which cerebral bleedings are a life-threatening complication of antiplatelet drugs. [33] [34] [35] While single or dual antiplatelet treatments have shown great potential in stroke prevention, 35 variable results have been reported for their use in the setting of acute ischemic stroke treatment. 36 Studies performed in animal models have found platelets contribute to ischemic stroke by participating in occlusive thrombus formation and embolization, but also by acting downstream of the occlusive thrombus, contributing to reperfusion injury and the no-reflow phenomenon. 37 It still a topic of debate whether similar phenomena contribute to human stroke pathophysiology; however, robust studies on platelet activation markers in the acute setting of stroke are lacking and their contribution to stroke outcomes has never thoroughly been investigated. Future studies should analyze whether circulating platelet aggregates are observed in stroke patients and whether these are able predict long-term stroke outcomes. All authors declare no conflicts of interest. F.D., A.A., and R.A.C. wrote the paper. On behalf of all the authors of the publication "Shining a light on platelet activation in COVID-19", I declare that all the authors have read, critically reviewed the paper, and agree to its publication. https://orcid.org/0000-0003-1442-3568 Abigail Ajanel https://orcid.org/0000-0002-4601-3769 Robert A. Campbell https://orcid.org/0000-0003-0027-694X Mechanisms of immunothrombosis in COVID-19 Massive image-based singlecell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19 Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19 Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a postmortem study d-dimer and death in critically Ill patients with coronavirus disease 2019 C-reactive protein and clinical outcomes in patients with COVID-19 Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19 Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19 Role of platelets in detection and regulation of infection Platelet and megakaryocyte roles in innate and adaptive immunity Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19 SARS-CoV-2 initiates programmed cell death in platelets Platelets amplify endotheliopathy in COVID-19 COVID-19 patients exhibit reduced procoagulant platelet responses Platelet gene expression and function in patients with COVID-19 Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease Platelets contribute to disease severity in COVID-19 Effects of low-dose aspirin on acute inflammatory responses in humans Acetylsalicylic acid inhibits intravascular coagulation during Staphylococcus aureus-induced sepsis in mice Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Effect of P2Y12 inhibitors on inflammation and immunity Effect of P2Y12 inhibitors on survival free of organ support among non-critically Ill hospitalized patients with COVID-19: a randomized clinical trial Antiplatelet therapy in patients with COVID-19-more is less? Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019 Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19 Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: a propensity score-matched analysis Bleeding risk of dual antiplatelet therapy after minor stroke or transient ischemic attack Meta-analysis of usefulness of antiplatelet therapy in ischemic stroke or transient ischemic attack Guideline for the prevention of stroke in patients with stroke and transient ischemic attack Antiplatelet therapy in ischemic stroke and transient ischemic attack Brothers in arms: platelets and neutrophils in ischemic stroke How to cite this article Shining a light on platelet activation in COVID-19